In the present review we discuss the complex interplay between BDNF signaling impairment, myelin disruption, and the progression of Alzheimer's disease, as well as the therapeutic potential of BDNF targeting in establishing a re-myelination approach in AD. The gene discussed is BDNF; the disease is Alzheimer disease.